Skip to main content
2026 CRT Conference Main banner

CRT 2026

Spotlight

Session:: Spotlight Session | Challenges in Clinical Trial Designs

Are Quality of Life Endpoints Reliable in Open-Label Trials?

Monday, March 9, 2026
8:05 AM - 8:13 AM EST
Location: Spotlight Theater

    Speaker(s)

  • Gregg W. Stone, MD, FACC, MSCAI

    Physician
    Mount Sinai
    New York, New York, United States

    Disclosure(s): Cardiac Success, Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Valfix, Xenter, Vascentis: Stock-privately held company (Ongoing); Cardiac Success, Occlutech, Ablative Solutions, Oxitope, Elixir, Impulse Dynamics, Asceneuron, Myochron, Vesalio: Consulting Fees (e.g., advisory boards) (Terminated); Colibri, Remote Cardiac Enablement, Valfix, Zoll, HeartFlow, Shockwave, Ancora, Adona Medical, Abbott, HighLife, Elucid Bio, Aria, Alleviant, FBR Medical, Bioventrix, MedHub, Biotyx Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Shockwave, Biosense-Webster, Bioventrix, Abbott, Abiomed, Cardiovascular Systems Inc, Phillips, Pulnovo, V-wave and PCORI via Weill Cornell Medical Center.: Grant/Research Support (Ongoing)